Pre-clinical Bruker Albira Si PET/SPECT/CT imaging system

临床前 Bruker Albira Si PET/SPECT/CT 成像系统

• 批准号: 10633022
• 负责人: Jason Thanh Lee
• 金额: $ 108.43万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-26 至 2024-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10633022
• 关键词: Acceleration; Anatomy; Animal Experimentation; Biological Assay; Biological Markers; Cancer Biology; Cell Therapy; Cyclotrons; Development; Diagnostic; Doctor of Philosophy; Education; Failure; Funding; Image; Imaging technology; Immunity; Immunotherapy; Informatics; Institution; Interdisciplinary Study; Lead; Minor; Modality; PET/CT scan; Physicians; Physics; Positron; Positron-Emission Tomography; Precision Health; Radiochemistry; Radioisotopes; Radiology Specialty; Radiopharmaceuticals; Research; Research Personnel; Research Project Grants; Resource Sharing; Scientist; Senior Scientist; Small Animal Imaging Systems; System; Systems Integration; Technology; Therapeutic; Tracer; United States National Institutes of Health; Vision; X-Ray Computed Tomography; animal imaging; biological systems; biomarker discovery; cancer therapy; clinical translation; end of life; experience; first-in-human; gene therapy; image guided; image-guided drug delivery; imaging facilities; imaging modality; imaging program; imaging system; in-vitro diagnostics; innovation; instrument; interest; medical schools; molecular imaging; multimodality; nervous system disorder; next generation; novel; novel diagnostics; nuclear imaging; pre-clinical; precision medicine; programs; radioligand; senior faculty; single photon emission computed tomography; synergism

PROJECT SUMMARY/ABSTRACT The Department of Radiology at the Stanford School of Medicine is a preeminent institution renown for developing next generation imaging technology, molecular imaging, in vitro diagnostics, image-guided therapeutics, and informatics for precision health. Our Molecular Imaging Program at Stanford (MIPS), a highly regarded interdisciplinary research division established in 2003, brings together scientists and physicians who share a common interest in developing and using state-of-the-art imaging technology and developing molecular imaging assays for studying intact biological systems. There is now a pressing unmet programmatic need for a multimodal small animal imaging system that offers state-of-the-art imaging available in the Bruker Albira Si PET/SPECT/CT. It will be an enabling technology at Stanford, creating new research opportunities for multi- tracer imaging, significantly broadening our repertoire of radionuclides beyond positron-emitters and accelerating novel radiopharmaceutical development and clinical translation in our theragnostics program. It will allow sunsetting of our once-state-of-the-art, but now end-of-life workhorse Inveon PET/CT, which has experienced increasing downtime due to failures. It will be placed in our comprehensive small animal imaging facility as a Stanford shared resource and supported by a team of PhD-level senior scientists. An integrated trimodal imaging system will immediately contribute to our well-established and growing radionuclide-based biomarker discovery program in diagnostics and radioligand therapy. The Major and Minor users we have assembled reflect junior through senior faculty with NIH-funded research projects and includes highly accomplished experts in their fields. They are particularly interested in multi-tracer applications and, therefore, an integrated system combining SPECT, PET and CT is especially needed. The nuclear imaging modalities would support our researchers who study image-guided drug delivery, cancer biology, neurological diseases, cancer cell and gene therapies, and immunity and immunotherapy, in addition to developing novel diagnostic and theragnostic radiopharmaceuticals and imaging strategies. SPECT is essential for researchers who need access to biomarkers outside of those for PET and for imaging more than one target concurrently. Both modalities, when combined with anatomical CT, are essential to advance novel radiopharmaceuticals from discovery to first-in-human clinical translation, and will be central to our expanding theragnostics activities. The addition of this instrument will converge with programmatic activities at Stanford: new state-of-the-art cyclotron and radiochemistry facility, first designated comprehensive Radiopharmaceutical Therapy Center of Excellence, growing interest in theragnostics and biomarker discovery, and new educational opportunities in biomedical physics, imaging and radionuclide-based therapy. The Albira system will create novel opportunities in small animal research and synergize with Stanford’s long-range vision to lead in biomedical innovation and advanced precision medicine.

项目概要/摘要 斯坦福大学医学院放射科是一所卓越的机构，因 开发下一代成像技术、分子成像、体外诊断、图像引导 我们斯坦福大学的分子成像项目 (MIPS) 是一项高度重视的项目。 2003 年成立的跨学科研究部门，汇集了科学家和医生， 在开发和使用最先进的成像技术以及开发分子生物学方面有着共同的兴趣 用于研究完整生物系统的成像测定现在迫切需要满足未满足的计划需求。 多模式小动物成像系统，可在 Bruker Albira Si 中提供最先进的成像 PET/SPECT/CT 将成为斯坦福大学的一项支持技术，为多学科领域创造新的研究机会。 示踪成像，显着拓宽了我们的放射性核素库，使其超出了正电子发射体，并加速了 我们的治疗诊断计划中的新型放射性药物开发和临床转化将成为可能。 我们曾经最先进但现已报废的主力 Inveon PET/CT 即将落幕，它经历了 由于故障而增加的停机时间将被放置在我们的综合小动物成像设施中。 斯坦福大学共享资源并由博士级资深科学家团队提供支持。 系统将立即为我们成熟且不断发展的基于放射性核素的生物标志物发现做出贡献 我们收集的主要和次要用户反映了初级用户的情况。 由参与 NIH 资助的研究项目的高级教师组成，其中包括各自领域卓有成就的专家。 他们对多示踪剂应用特别感兴趣，因此需要一个结合了多种示踪剂的集成系统 尤其需要 SPECT、PET 和 CT 核成像方式来支持我们的研究人员。 研究图像引导药物输送、癌症生物学、神经系统疾病、癌细胞和基因疗法，以及 免疫和免疫治疗，以及开发新型诊断和治疗诊断放射性药物 SPECT 对于需要获取其他生物标志物的研究人员来说至关重要。 PET 和同时对多个目标进行成像，这两种方式与解剖 CT 相结合， 对于推进新型放射性药物从发现到首次人体临床转化至关重要，并将 成为我们扩大治疗诊断学活动的核心。该仪器的添加将与 斯坦福大学的规划活动：首次指定新的最先进的回旋加速器和放射化学设施 综合性放射药物治疗卓越中心，对治疗诊断学和治疗学的兴趣日益浓厚 生物标志物的发现以及生物医学物理、成像和放射性核素方面的新教育机会 Albira 系统将为小动物研究创造新的机会，并与斯坦福大学的系统产生协同作用。 引领生物医学创新和先进精准医学的长远愿景。